Lightnews — Scholar-powered news

Sarah Cannon Research Institute @scri.com · 4d

November is #LungCancerAwarenessMonth.
#SCRI's Dr. Melissa Johnson joined NewsChannel 5 to discuss how early detection and clinical trials are transforming lung cancer care. From low-dose CT scans to bispecifics, the future of treatment is here.
www.newschannel5.com/news/let-me-...

1

Sarah Cannon Research Institute @scri.com · 12d

New data from HER2CLIMB-05: Tucatinib added to first-line maintenance therapy improves PFS in HER2+ metastatic breast cancer.
Dr. Erika Hamilton of SCRI shares insights on this promising approach.
Full Cancer Network story:
www.cancernetwork.com/view/tucatin...
#Oncology #BreastCancer #HER2CLIMB05

Tucatinib Regimen Improves PFS in HER2+ Metastatic Breast Cancer | CancerNetwork

The safety profile of tucatinib plus trastuzumab and pertuzumab was consistent with the established profiles of each individual agent.

www.cancernetwork.com

Sarah Cannon Research Institute @scri.com · 14d

Journalist Amy Robach opens up about discovering breast cancer after a filmed mammogram. SCRI’s Dr. Erika Hamilton shares expert tips on risk and prevention on the Drew Barrymore Show.
Watch here: www.thedrewbarrymoreshow.com/videos/journ...
#BreastCancerAwareness #SCRIExperts

Journalist Who Discovered She Had Breast Cancer After Filming Mammogram Segment Shares Her Story

www.thedrewbarrymoreshow.com

Sarah Cannon Research Institute @scri.com · 14d

SCRI expert Dr. Ben Garmezy shares insights on testicular cancer diagnosis, treatment choices, and patient education in this CURE Today feature.
Read more:
www.curetoday.com/view/stage-1...
#CancerEducation #TesticularCancer #SCRI

Stage 1 Testicular Cancer: A Patient Education Overview | CURE

From diagnosis to treatment, here is what patients need to know about stage 1 testicular cancer.

www.curetoday.com

Sarah Cannon Research Institute @scri.com · 19d

PHAROS trial update: Half of treatment-naïve patients with BRAF V600E–mutant NSCLC treated with encorafenib + binimetinib are alive at 4 years.
Shoutout to Dr. Melissa Johnson for her leadership in advancing targeted therapy!
🔗 www.ajmc.com/view/long-te...
#CancerCare #Oncology #TargetedTherapy

Long-Term Data for PHAROS Show Half of Treatment-Naïve Patients Receiving Encorafenib Plus Binimetinib Alive at 4 Years | AJMC

A mini oral session at ESMO of targeted therapy in non-small cell lung cancer included treatments that showed effectiveness in brain metastases.

www.ajmc.com

Sarah Cannon Research Institute @scri.com · 20d

The future of oncology is here: AI-powered decisions, precision medicine, and collaborative care models. At #PCOC2025, experts—including Dr. Vivek Subbiah—explored how these innovations will improve patient outcomes.

🔗 www.ajmc.com/view/experts...
#HealthcareInnovation #Oncology #AI

Experts Highlight AI, Innovation, and Collaboration as Key PCOC Takeaways | AJMC

Five experts share their key takeaways from Patient-Centered Oncology Care® (PCOC) 2025, highlighting AI integration and collaboration to improve care.

www.ajmc.com

Sarah Cannon Research Institute @scri.com · Oct 9

Your breast cancer risk is personal—and understanding it is powerful.
SCRI's Dr. Denise Yardley shares how genetic testing is changing prevention on @newschannel5plus.bsky.social .
🎥 Watch: bit.ly/DrYardleyBCAM
#BCAM #BreastCancerAwareness #EarlyDetection #SCRI

Sarah Cannon Research Institute @scri.com · Oct 6

We’re celebrating Dr. Howard “Skip” Burris’s remarkable career as he prepares to retire as President & CMO of SCRI.
His legacy: 850+ first-in-human trials, countless lives impacted. 💙

Welcome new leaders and read the full update:
www.scri.com/news/scri-an...

1

Sarah Cannon Research Institute @scri.com · Oct 2

At 45, Bryan was diagnosed with advanced prostate cancer.
A BRCA mutation led him to a clinical trial through SCRI at Texas Oncology.
Today, his PSA levels are undetectable—and he’s thriving. 💙
#ProstateCancer #BRCA #SCRI #TexasOncology #USOncologyNetwork #ClinicalTrials #CancerResearch

Sarah Cannon Research Institute @scri.com · Sep 29

Bill, 76, joined a clinical trial at SCRI to treat stage IV prostate cancer. His goal: dance at his daughter’s wedding. ✅
Now celebrating a grandchild & still practicing law—while seeing a 15% reduction in disease.
Hope lives here.
🔗 www.scri.com/patients/?co...
#SCRI #ClinicalTrials #ProstateCancer

Sarah Cannon Research Institute @scri.com · Sep 26

🎧 SCRI’s Dr. Garmezy & Dr. Bupathi share expert insights on treating variant histologies in GU cancers at #WorldGU2025 on Oncology Decoded.
🔗 www.cancernetwork.com/view/episode...
#SCRI #CancerResearch #GUOncology #OncologyDecoded

Episode 12: Variant Histology Treatment Considerations From World GU 2025 | CancerNetwork

Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.

www.cancernetwork.com

Sarah Cannon Research Institute @scri.com · Sep 25

Mary is proof that hope and research go hand in hand.
She’s in a clinical trial for IV #ovariancancer at #SCRI at Mary Crowley—and her disease has remained stable since March.
She’s walked the Camino de Santiago, joined the Lourdes Pilgrimage, & got a tattoo to celebrate it all. #PatientStories

1

Sarah Cannon Research Institute @scri.com · Sep 19

Dr. Hans Lee & Dr. Kris Patel from SCRI Oncology share how new therapies like CAR T-cell treatment are changing lives.

📺 Watch the News Channel 5 segment: www.youtube.com/watch?v=hg4_...
#BloodCancerAwareness #LymphomaAwareness #CancerCare #SCRI

How Blood Cancer Research Is Advancing Treatment | Dr. Hans Lee & Dr. Kris Patel on News Channel 5

YouTube video by Sarah Cannon Research Institute

www.youtube.com

Sarah Cannon Research Institute @scri.com · Sep 12

Dr. Jason Henry featured on @DenverChannel discussing early data from a promising #pancreaticcancer vaccine.
“This is one of the most exciting times in pancreatic cancer research in the last 100 years.”
#SCRI #CancerResearch #ClinicalTrials
www.denver7.com/lifestyle/he...

Early data for new pancreatic cancer vaccine generating hope among patients, researchers

Early data for a new vaccine for pancreatic cancer is generating some hope among patients and researchers.

www.denver7.com

Sarah Cannon Research Institute @scri.com · Sep 5

“Prostate cancer is often treatable—if caught early.”
Dr. Benjamin Garmezy shares why early screening matters and how new therapies are offering hope.
🎥 Watch the clip: youtu.be/tMnvf31VWN8
#ProstateCancerAwareness #MensHealth #CancerResearch #SCRIOncology

What You Need to Know About Prostate Cancer Awareness | Dr. Benjamin Garmezy on News Channel 5

YouTube video by Sarah Cannon Research Institute

youtu.be

Sarah Cannon Research Institute @scri.com · Sep 2

Joseph, a physician & mountain biking coach, was diagnosed with AML in 2023. A clinical trial at SCRI helped him return to biking, coaching, and living fully. 💬 Read his story: www.scri.com/patients/?co...
#AML #SCRI #ClinicalTrials #Hope

Sarah Cannon Research Institute @scri.com · Aug 27

New studies in ASH’s Blood Advances show significant quality-of-life gains for patients with #SickleCell & #BetaThalassemia.

From hospital beds to classrooms & workplaces, read how CRISPR is giving new opportunities to pts.

#GeneTherapy #ExaCel #CRISPR #Hematology

American Society of Hematology @ash.hematology.org · Aug 27

Gene therapy is changing lives! For patients with sickle cell disease and beta thalassemia, exa-cel means freedom from hospital visits and a renewed quality of life. 🔗 Learn more in the press release: https://bit.ly/3HTDvM8

@hfrangoul.bsky.social

Sarah Cannon Research Institute @scri.com · Aug 26

Dr. Hans Lee joins OncLive On Air to discuss FDA approval of linvoseltamab for relapsed/refractory multiple myeloma. A new option for patients with limited therapies.

🔗 www.onclive.com/view/fda-app...

#MultipleMyeloma #SCRI #FDAApproval

FDA Approval Insights: Linvoseltamab in Relapsed/Refractory Multiple Myeloma: With Nisha Joseph, MD; and Hans Lee, MD

Drs Lee and Joseph discuss the significance of the FDA approval of linvoseltamab for the treatment of patients with relapsed/refractory multiple myeloma.

www.onclive.com

Sarah Cannon Research Institute @scri.com · Aug 25

Kim’s story is a powerful reminder of what clinical trials can offer.
After receiving treatment through SCRI and Alliance Cancer Specialists, today, she’s an advocate, fundraiser, and survivor.
www.scri.com/patients/?co...
#SCRI #OvarianCancerAwareness #ClinicalTrialsMatter #PatientStories

1

Sarah Cannon Research Institute @scri.com · Aug 22

Early data from a personalized mRNA vaccine shows promise in delaying recurrence in pancreatic cancer. Dr. Jason Henry shares why this is generating hope.

🔗 www.onclive.com/view/persona...
#PancreaticCancer #CancerVaccine #SCRI

Personalized Cancer Vaccine Leads to Delays in Pancreatic Cancer Recurrence

Adjuvant treatment with the personalized neoantigen vaccine, autogene cevumeran, delayed pancreatic cancer recurrence in pancreatic ductal adenocarcinoma.

www.onclive.com

1

Sarah Cannon Research Institute @scri.com · Aug 21

FDA accepts NDA for vepdegestrant in ER+/HER2– metastatic breast cancer. Dr. Erika Hamilton highlights the VERITAC-2 trial’s impact on this promising therapy.

🔗 www.onclive.com/view/fda-acc...
#BreastCancer #VERITAC2 #SCRI #FDAApproval

FDA Accepts NDA for Vepdegestrant in ESR1-Mutated, ER+/HER2– Breast Cancer

The FDA accepted an NDA for vepdegestrant in ER-positive, HER2-negative advanced breast cancer harboring ESR1 mutations after prior endocrine therapy.

www.onclive.com

Sarah Cannon Research Institute @scri.com · Aug 20

In Oncology Decoded, SCRI's Drs. Bupathi and Garmezy, discuss evolving strategies for treating urothelial carcinoma beyond first-line therapy, particularly in light of recent FDA approvals.

Listen to the episode: www.cancernetwork.com/view/episode...

Sarah Cannon Research Institute @scri.com · Aug 19

Lisa’s story is one of resilience and research.

Diagnosed with triple-negative breast cancer while pregnant, she beat the odds through a clinical trial at SCRI.
Nearly 20 years later, she’s cancer-free — and her journey continues to inspire.
www.scri.com/patients/?co...

#PatientStories

Sarah Cannon Research Institute @scri.com · Aug 18

Welcome Dr. Sarah Premji to Sarah Cannon Research Institute! As Assistant Director of Breast Cancer Research, she brings deep expertise and passion for patient-centered care.

📄 Full story: www.scri.com/news/sarah-c...
#SCRI #CancerResearch #Leadership #BreastCancer

Sarah Cannon Research Institute @scri.com · Aug 15

🧬 “AQUILA is a big trial… and there’s a trend toward improved OS.”
– SCRI expert, Dr. Burke on daratumumab for high-risk smoldering #MultipleMyeloma in Targeted Therapies in Oncology.

ODAC votes 6–2 in favor. FDA decision pending.
📖 Read: www.targetedonc.com/view/dr-burk...

Dr Burke Discusses Daratumumab in Smoldering Myeloma

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and its implications for clinical practice.

www.targetedonc.com